OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ghia on the Rationale for the CAPTIVATE Trial in CLL

June 29th 2021

Paolo Ghia, MD, PhD, discusses the rationale for the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Ahmed on the Need for Multidisciplinary Care in HER2+ Breast Leptomeningeal Disease

June 29th 2021

Kamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.

Dr. Burtness on the Efficacy of Checkpoint Inhibitors in Head & Neck Cancer

June 29th 2021

Barbara Burtness, MD, discusses the efficacy of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.

Dr. Graham on Utilizing Biomarkers to Guide Treatment in Intrahepatic Cholangiocarcinoma

June 29th 2021

Rondell Graham, MBBS, discusses utilizing biomarkers to guide treatment for patients with intrahepatic cholangiocarcinoma.

Dr. Heimberger on the Variability of Responses in Glioblastoma

June 25th 2021

Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.

Dr. Weiss on Selecting Optimal Radiation Therapy for Brain Metastases

June 25th 2021

Stephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.

Dr. Ailawadhi on the Safety Profile of Lisaftoclax in CLL

June 25th 2021

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Dr. Halmos on the Efficacy of COVID-19 Vaccines in Patients With Cancer

June 25th 2021

Balazs Halmos, MD, discusses the efficacy of the COVID-19 vaccines in patients with cancer.

Dr. Tawbi on the Safety Profile of Relatlimab Plus Nivolumab in Advanced Melanoma

June 24th 2021

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in advanced melanoma.

Dr. Bardia on the Rationale for the AMEERA-5 Trial in ER+/HER2- Breast Cancer

June 24th 2021

Aditya Bardia, MD, MPH, discusses the rationale for the ongoing phase 3 AMEERA-5 trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Schram on the Results of the Phase 1/2 eNRGy Trial in NRG1+ Solid Tumors

June 24th 2021

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.

Dr. Mesa on the Unique Characteristics of Pacritinib in Myelofibrosis

June 24th 2021

Ruben A. Mesa, MD, discusses the unique characteristics of pacritinib in the treatment of patients with myelofibrosis.

Dr. Sonbol on the Role of Pembrolizumab in Gastric Cancer

June 24th 2021

Bassam Sonbol, MD, discusses the role of pembrolizumab in the treatment of patients with gastric cancer.

Dr. Malhotra on the Safety Profile of Plinabulin/Nivolumab/Ipilimumab in Relapsed SCLC

June 23rd 2021

Jyoti Malhotra, MD, MPH, discusses the safety profile of plinabulin in combination with nivolumab and ipilimumab in relapsed/refractory small cell lung cancer.

Dr. Martin on the Findings of a Real-World Analysis of Outcomes in MCL

June 23rd 2021

Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.

Dr. Nguyen on Enrollment Disparities in Pivotal Clinical Trials in Oncology

June 23rd 2021

Ryan Nguyen, DO, discusses enrollment disparities in pivotal clinical trials in oncology.

Dr. Ahn on Navigating Among Available Therapeutic Options in Advanced, Unresectable HCC

June 22nd 2021

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC

June 22nd 2021

Alexander Spira, MD, PhD, FACP, discusses the updated results of the phase 1 CHRYSALIS trial in EGFR-mutant non–small cell lung cancer.

Dr. Liu on the Rationale for the ARROW Trial in RET Fusion+ NSCLC

June 22nd 2021

Stephen Liu, MD, discusses the rationale for the ongoing phase 1/2 ARROW trial in RET fusion–positive non–small cell lung cancer.

Dr. Abedin on Managing Cardiac Toxicities With Acalabrutinib vs Ibrutinib in CLL

June 22nd 2021

Sameem Abedin, MD, discusses managing cardiac toxicities with acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia.